Achiko AG (Achiko AG) ROCE % : 0.00% (As of Jun. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Achiko AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Achiko AG's annualized ROCE % for the quarter that ended in Jun. 2022 was 0.00%.

Achiko AG ROCE % Historical Data

The historical data trend for Achiko AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achiko AG ROCE % Chart

Achiko AG Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

ROCE %

-9,147.95

Achiko AG Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
ROCE %	Get a 7-Day Free Trial			-	-	-	-	-

Achiko AG ROCE % Calculation

Achiko AG's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	-8.443	/	( ( (1.772 - 5.496)	+	(1.914 - 4.123) )	/ 2 )
	=	-8.443	/	( (-3.724	+	-2.209)	/ 2 )
	=	-8.443	/	-2.9665
	=	284.61 %

Achiko AG's ROCE % of for the quarter that ended in Jun. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2022 )		(Q: Dec. 2021 )		(Q: Jun. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2022 )		(Q: Dec. 2021 )		(Q: Jun. 2022 )
	=	-3.962	/	( ( (1.914 - 4.123)	+	(2.348 - 5.384) )	/ 2 )
	=	-3.962	/	( ( -2.209	+	-3.036 )	/ 2 )
	=	-3.962	/	-2.6225
	=	0 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2022) EBIT data.

Achiko AG (OTCPK:ACHKF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Achiko AG ROCE % Related Terms

Thank you for viewing the detailed overview of Achiko AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Achiko AG (Achiko AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Achiko AG (OTCPK:ACHKF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Tessinerplatz 7, Zurich, CHE, CH-8002

Website

https://www.achiko.com

Achiko AG is developing disruptive diagnostic solutions that put people first. The company product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX, and companion health apps via its digital mobile health technology division, Teman Sehat. The AptameX DNA aptamer tests can be rapidly chemically synthesized, are cost-effective, and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate, and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.